Recent data of COVID-19 patients who received ACE inhibitors or AT1 antagonists as an accompanying therapy for their high blood pressure have been reported, with some studies demonstrating a positive effect on the survival rate of COVID-19 patients, and others exhibiting no benefit [39,40,41]. This evidence concerns the gene AGTR1 and hypertensive disorder.